PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 26, 2026Cancer Medicine0 citationsOpen Access

Survival Outcomes and Sensitivity of PARP Inhibitors in Platinum‐Sensitive Ovarian Cancer: A Retrospective Study

View Full Paper
XZXiu ZhangZWZhibin WangYGYuhui Gu

Key Points

  • This research aims to evaluate survival outcomes and identify sensitivity markers for PARP inhibitors in ovarian cancer patients.
  • Conducted a retrospective analysis of Chinese ovarian cancer patients receiving PARP inhibitor maintenance therapy.
  • Identified biomarkers TFRC and PRNP for predicting PARPi sensitivity.
  • Over 20% of patients exhibited primary resistance to PARP inhibitors.
  • TFRC and PRNP are potential biomarkers for assessing PARPi sensitivity, requiring further validation.

Abstract

PARPi maintenance therapy demonstrates substantial clinical benefit in real-world Chinese patients with ovarian cancer. However, over 20% exhibit primary resistance. TFRC and PRNP represent promising biomarkers for predicting PARPi sensitivity and warrant further validation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69edabb84a46254e215b392chttps://doi.org/10.1002/cam4.71850
Ask AI
Helpful
Bookmark
Share
View Full Paper